{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,10]],"date-time":"2026-06-10T23:41:36Z","timestamp":1781134896094,"version":"3.54.1"},"reference-count":31,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,8,1]],"date-time":"2021-08-01T00:00:00Z","timestamp":1627776000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,8,1]],"date-time":"2021-08-01T00:00:00Z","timestamp":1627776000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,8,1]],"date-time":"2021-08-01T00:00:00Z","timestamp":1627776000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2021,8,1]],"date-time":"2021-08-01T00:00:00Z","timestamp":1627776000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2021,8,1]],"date-time":"2021-08-01T00:00:00Z","timestamp":1627776000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2021,8,1]],"date-time":"2021-08-01T00:00:00Z","timestamp":1627776000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2021,8,1]],"date-time":"2021-08-01T00:00:00Z","timestamp":1627776000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jocn-journal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Clinical Neuroscience"],"published-print":{"date-parts":[[2021,8]]},"DOI":"10.1016\/j.jocn.2021.06.002","type":"journal-article","created":{"date-parts":[[2021,6,12]],"date-time":"2021-06-12T12:24:29Z","timestamp":1623500669000},"page":"225-232","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":20,"special_numbering":"C","title":["Effects of argatroban therapy for stroke patients: A meta-analysis"],"prefix":"10.1016","volume":"90","author":[{"given":"Xiaojun","family":"Hou","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chunfeng","family":"Jin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chengli","family":"Pan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xichun","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jujun","family":"Xue","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhenghua","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dan","family":"Qi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"2","key":"10.1016\/j.jocn.2021.06.002_b0005","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1055\/s-0038-1649503","article-title":"Global Burden of Stroke","volume":"38","author":"Katan","year":"2018","journal-title":"Semin Neurol"},{"issue":"9","key":"10.1016\/j.jocn.2021.06.002_b0010","doi-asserted-by":"crossref","first-page":"2450","DOI":"10.1161\/STROKEAHA.117.017320","article-title":"Mechanical thrombectomy outcomes with and without intravenous thrombolysis in stroke patients: a meta-analysis","volume":"48","author":"Mistry","year":"2017","journal-title":"Stroke"},{"issue":"11","key":"10.1016\/j.jocn.2021.06.002_b0015","doi-asserted-by":"crossref","DOI":"10.1016\/j.jstrokecerebrovasdis.2020.105204","article-title":"Safety of mechanical thrombectomy with combined intravenous thrombolysis in stroke treatment 4.5 to 9 hours from symptom onset","volume":"29","author":"Reiff","year":"2020","journal-title":"J Stroke Cerebrovasc Dis"},{"key":"10.1016\/j.jocn.2021.06.002_b0020","doi-asserted-by":"crossref","first-page":"e341","DOI":"10.1016\/j.wneu.2019.08.151","article-title":"Safety and feasibility of using argatroban immediately after mechanical thrombectomy for large artery occlusion","volume":"132","author":"Kim","year":"2019","journal-title":"World Neurosurg"},{"issue":"6","key":"10.1016\/j.jocn.2021.06.002_b0025","doi-asserted-by":"crossref","first-page":"1608","DOI":"10.1161\/STROKEAHA.117.016720","article-title":"Randomized, multicenter trial of ARTSS-2 (argatroban with recombinant tissue plasminogen activator for acute stroke)","volume":"48","author":"Barreto","year":"2017","journal-title":"Stroke"},{"issue":"6","key":"10.1016\/j.jocn.2021.06.002_b0030","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1001\/jamaneurol.2019.0072","article-title":"Antiplatelet therapy vs anticoagulation therapy in cervical artery dissection: the cervical artery dissection in stroke study (CADISS) randomized clinical trial final results","volume":"76","author":"Markus","year":"2019","journal-title":"JAMA Neurol"},{"issue":"4","key":"10.1016\/j.jocn.2021.06.002_b0035","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1177\/1076029616660762","article-title":"Antiplatelet and anticoagulant therapies for prevention of ischemic stroke","volume":"23","author":"Kapil","year":"2017","journal-title":"Clin Appl Thromb Hemost"},{"issue":"20","key":"10.1016\/j.jocn.2021.06.002_b0040","doi-asserted-by":"crossref","first-page":"1444","DOI":"10.1056\/NEJMoa011258","article-title":"A comparison of warfarin and aspirin for the prevention of recurrent ischemic stroke","volume":"345","author":"Mohr","year":"2001","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.jocn.2021.06.002_b0045","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1159\/000092331","article-title":"Comparison of warfarin versus aspirin for the prevention of recurrent stroke or death: subgroup analyses from the Warfarin-Aspirin Recurrent Stroke Study","volume":"22","author":"Sacco","year":"2006","journal-title":"Cerebrovasc Dis (Basel, Switzerland)"},{"key":"10.1016\/j.jocn.2021.06.002_b0050","article-title":"Argatroban increased the basal vein drainage and improved outcomes in acute paraventricular ischemic stroke patients","volume":"26","author":"Liu","year":"2020","journal-title":"Med Sci Monit"},{"key":"10.1016\/j.jocn.2021.06.002_b0055","doi-asserted-by":"crossref","DOI":"10.1177\/1076029620904131","article-title":"Effect of argatroban combined with dual antiplatelet therapy on early neurological deterioration in acute minor posterior circulation ischemic stroke","volume":"26","author":"Zhou","year":"2020","journal-title":"Clin Appl Thromb Hemost"},{"issue":"10","key":"10.1016\/j.jocn.2021.06.002_b0060","doi-asserted-by":"crossref","first-page":"862","DOI":"10.1080\/01616412.2018.1495882","article-title":"Argatroban plus aspirin versus aspirin in acute ischemic stroke","volume":"40","author":"Chen","year":"2018","journal-title":"Neurol Res"},{"key":"10.1016\/j.jocn.2021.06.002_b0065","doi-asserted-by":"crossref","DOI":"10.1016\/j.clineuro.2020.106233","article-title":"Early and long-term outcomes of argatroban use in patients with acute noncardioembolic stroke","volume":"198","author":"Chen","year":"2020","journal-title":"Clin Neurol Neurosurg"},{"issue":"8","key":"10.1016\/j.jocn.2021.06.002_b0070","doi-asserted-by":"crossref","first-page":"1057","DOI":"10.1001\/archneur.63.8.1057","article-title":"Argatroban tPA stroke study: study design and results in the first treated cohort","volume":"63","author":"Sugg","year":"2006","journal-title":"Arch Neurol"},{"issue":"2","key":"10.1016\/j.jocn.2021.06.002_b0075","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1161\/STROKEAHA.115.011250","article-title":"Outcomes of argatroban treatment in patients with atherothrombotic stroke: observational nationwide study in Japan","volume":"47","author":"Wada","year":"2016","journal-title":"Stroke"},{"key":"10.1016\/j.jocn.2021.06.002_b0080","doi-asserted-by":"crossref","DOI":"10.1136\/bmj.d5928","article-title":"The cochrane collaboration's tool for assessing risk of bias in randomised trials","volume":"343","author":"Higgins","year":"2011","journal-title":"BMJ"},{"issue":"9","key":"10.1016\/j.jocn.2021.06.002_b0085","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1007\/s10654-010-9491-z","article-title":"Critical evaluation of the Newcastle-Ottawa scale for the assessment of the quality of nonrandomized studies in meta-analyses","volume":"25","author":"Andreas","year":"2010","journal-title":"Eur J Epidemiol"},{"key":"10.1016\/j.jocn.2021.06.002_b0090","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1136\/bmj.315.7109.629","article-title":"Bias in meta-analysis detected by a simple, graphical test","volume":"315","author":"Egger","year":"1997","journal-title":"BMJ"},{"issue":"12","key":"10.1016\/j.jocn.2021.06.002_b0095","doi-asserted-by":"crossref","first-page":"3647","DOI":"10.1016\/j.jstrokecerebrovasdis.2018.08.036","article-title":"Safety and feasibility of argatroban, recombinant tissue plasminogen activator, and intra-arterial therapy in stroke (ARTSS-IA Study)","volume":"27","author":"Berekashvili","year":"2018","journal-title":"J Stroke Cerebrovasc Dis"},{"issue":"8","key":"10.1016\/j.jocn.2021.06.002_b0100","doi-asserted-by":"crossref","first-page":"2175","DOI":"10.1016\/j.jstrokecerebrovasdis.2018.03.016","article-title":"Retrospective analysis of argatroban in 353 patients with acute noncardioembolic stroke","volume":"27","author":"Oguro","year":"2018","journal-title":"J Stroke Cerebrovasc Dis"},{"issue":"7","key":"10.1016\/j.jocn.2021.06.002_b0105","doi-asserted-by":"crossref","first-page":"1677","DOI":"10.1161\/01.STR.0000131549.20581.ba","article-title":"Argatroban anticoagulation in patients with acute ischemic stroke (ARGIS-1): a randomized, placebo-controlled safety study","volume":"35","author":"LaMonte","year":"2004","journal-title":"Stroke"},{"key":"10.1016\/j.jocn.2021.06.002_b0110","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.nbd.2012.09.004","article-title":"PAR-1 antagonist SCH79797 ameliorates apoptosis following surgical brain injury through inhibition of ASK1-JNK in rats","volume":"50","author":"Manaenko","year":"2013","journal-title":"Neurobiol Dis"},{"issue":"10","key":"10.1016\/j.jocn.2021.06.002_b0115","doi-asserted-by":"crossref","first-page":"2348","DOI":"10.1161\/STROKEAHA.110.584920","article-title":"Thrombin mediates severe neurovascular injury during ischemia","volume":"41","author":"Chen","year":"2010","journal-title":"Stroke"},{"key":"10.1016\/j.jocn.2021.06.002_b0120","first-page":"195","article-title":"Mild hypothermia enhances the neuroprotective effects of a selective thrombin inhibitor following transient focal ischemia in rats","volume":"86","author":"Kamiya","year":"2003","journal-title":"Acta Neurochir Suppl"},{"issue":"2","key":"10.1016\/j.jocn.2021.06.002_b0125","doi-asserted-by":"crossref","first-page":"780","DOI":"10.1016\/S0022-3565(25)20663-2","article-title":"Effects of a thrombin inhibitor, argatroban, on ischemic brain damage in the rat distal middle cerebral artery occlusion model","volume":"278","author":"Kawai","year":"1996","journal-title":"J Pharmacol Exp Ther"},{"issue":"4","key":"10.1016\/j.jocn.2021.06.002_b0130","doi-asserted-by":"crossref","first-page":"1530","DOI":"10.1161\/STROKEAHA.108.531699","article-title":"Thrombin inhibition by argatroban ameliorates early brain injury and improves neurological outcomes after experimental subarachnoid hemorrhage in rats","volume":"40","author":"Sugawara","year":"2009","journal-title":"Stroke"},{"issue":"2","key":"10.1016\/j.jocn.2021.06.002_b0135","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1111\/cei.12220","article-title":"Neuroprotective effects of argatroban and C5a receptor antagonist (PMX53) following intracerebral haemorrhage","volume":"175","author":"Li","year":"2014","journal-title":"Clin Exp Immunol"},{"issue":"3","key":"10.1016\/j.jocn.2021.06.002_b0140","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1016\/j.thromres.2011.11.001","article-title":"Mechanisms of platelet activation by thrombin: a short history","volume":"129","author":"De Candia","year":"2012","journal-title":"Thromb Res"},{"issue":"5","key":"10.1016\/j.jocn.2021.06.002_b0145","doi-asserted-by":"crossref","first-page":"626","DOI":"10.1182\/blood-2015-04-638387","article-title":"Signaling-mediated cooperativity between glycoprotein Ib-IX and protease-activated receptors in thrombin-induced platelet activation","volume":"127","author":"Estevez","year":"2016","journal-title":"Blood"},{"issue":"6","key":"10.1016\/j.jocn.2021.06.002_b0150","doi-asserted-by":"crossref","first-page":"916","DOI":"10.1055\/s-0039-1685139","article-title":"The direct thrombin inhibitors dabigatran and lepirudin inhibit GPIb\u03b1-mediated platelet aggregation","volume":"119","author":"Trabold","year":"2019","journal-title":"Thromb Haemost"},{"issue":"5","key":"10.1016\/j.jocn.2021.06.002_b0155","doi-asserted-by":"crossref","DOI":"10.1016\/j.jstrokecerebrovasdis.2021.105677","article-title":"Risk of early bleeding with dual antiplatelet therapy in acute stroke and transient ischemic attack regardless of NIHSS admission","volume":"30","author":"Scavasine","year":"2021","journal-title":"J Stroke Cerebrovasc Dis"}],"container-title":["Journal of Clinical Neuroscience"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0967586821002976?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0967586821002976?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,18]],"date-time":"2025-10-18T21:28:22Z","timestamp":1760822902000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0967586821002976"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,8]]},"references-count":31,"alternative-id":["S0967586821002976"],"URL":"https:\/\/doi.org\/10.1016\/j.jocn.2021.06.002","relation":{},"ISSN":["0967-5868"],"issn-type":[{"value":"0967-5868","type":"print"}],"subject":[],"published":{"date-parts":[[2021,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Effects of argatroban therapy for stroke patients: A meta-analysis","name":"articletitle","label":"Article Title"},{"value":"Journal of Clinical Neuroscience","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jocn.2021.06.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}